The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Klein, Jan M ^a   Henke, Alexander ^a   Sauer, Maike ^a   Bessler, Martina ^a   Reiners, Katrin S ^a   Engert, Andreas ^a   Hansen, Hinrich P ^a   Von Strandmann, Elke Pogge ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS, CD30; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; DEOXYCYTIDINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; IMMUNOCONJUGATES; INDOLES; INTERFERON-GAMMA; LYMPHOCYTES; MICROSCOPY, FLUORESCENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894360145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079502     Document Type: Article

References (17)

1. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A (2010) The classical hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221: 248-263.
2. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, et al. (2012) Panobinostat in patients with relapsed/refractory hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 30: 2197-2203.
3. Drexler HG (1993) Recent results on the biology of hodgkin and reed-sternberg cells. II. continuous cell lines. Leuk Lymphoma 9: 1-25.
4. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, et al. (2012) The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in hodgkin lymphoma cell lines. Blood 119: 4017-4025.
5. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, et al. (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 11136-11145. (Pubitemid 41713385)
6. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, et al. (2008) NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111: 1428-1436. (Pubitemid 351213430)
7. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, et al. (2002) Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in hodgkin-reed-sternberg cells. Oncogene 21: 2493-2503. (Pubitemid 34438102)
8. Kewitz S, Bernig T, Staege MS (2012) Histone deacetylase inhibition restores cisplatin sensitivity of hodgkin's lymphoma cells. Leuk Res 36: 773-778.
9. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J,Jr. (2007) Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 581: 1317-1322. (Pubitemid 46452605)
10. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, et al. (2013) Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther doi:10.1038/mt.2013.14.
11. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, et al. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in hodgkin lymphoma cell lines. Blood 112: 1424-1433.
12. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, et al. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-hodgkin's lymphoma. J Clin Oncol 17: 3786-3792.
13. Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, et al. (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage hodgkin lymphoma. Blood 118: 6292-6298.
14. Fujiwara Y, Shiba H, Iwase R, Haruki K, Furukawa K, et al. (2013) Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice. J Am Coll Surg 216: 320-32.e3.
15. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285. (Pubitemid 43736578)
16. von Tresckow B, Kallen KJ, von Strandmann EP, Borchmann P, Lange H, et al. (2004) Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 172: 4324-4331. (Pubitemid 38375247)
17. von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, et al. (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107: 1955-1962. (Pubitemid 43289377)